An oral regimen of once-daily budesonide was significantly more effective than mesalamine in inducing clinical and histologic remission in patients with lymphocytic colitis, researchers have found.
The phase 3, randomized double-blind study, involving 30 centers in eight European countries, showed that budesonide outperformed placebo for all end points, and was better than mesalamine for most outcomes. The researchers presented their findings at the 2018 Digestive Disease Week (abstract 816).